Johnson & Johnson (JNJ)

Over the past six months, Johnson & Johnson's stock price has seen a notable increase. As of January 13, 2026, the share price was $213.99, representing a 45.17% increase over the past 12 months. On January 9, 2026, the share price was $204.39, an increase of 41.48% from January 13, 2025. In the past month, the stock decreased by 0.88%. Recent news includes Johnson & Johnson presenting at the 44th Annual J.P. Morgan Healthcare Conference and reporting durable responses with RYBREVANT in metastatic colorectal cancer. In Q4 2024, Johnson & Johnson posted sales in line with estimates, with revenue growing 5.3% year-on-year to $22.52 billion.

While general seasonal trends can be observed in asset performance across various markets, Johnson & Johnson focuses on robust demand planning to meet customer needs effectively. The company has undertaken initiatives to transform its demand planning function to predict customer needs faster, improve forecast accuracy, and optimize external manufacturing operations to maintain appropriate stock availability. Johnson & Johnson's annualized revenue growth over the last two years has been consistent with its five-year trend, suggesting a steady demand for its products. However, analysts anticipate a slight deceleration in revenue growth over the next 12 months, indicating potential demand challenges that the company is actively addressing through its planning and operational strategies.

Johnson & Johnson (J&J) is a multinational corporation specializing in pharmaceuticals, biotechnology, and medical technologies, headquartered in New Brunswick, New Jersey. The company operates through its various operating companies and is a component of the Dow Jones Industrial Average. J&J is recognized as one of the world's most valuable companies and holds a prime credit rating of AAA. The company's business is primarily segmented into innovative medicines and medical technologies. Historically, it also included consumer health products, but this segment was spun off into a new public company, Kenvue, in May 2023, with Johnson & Johnson initially retaining a controlling stake. Key pharmaceutical products include treatments for immune disorders, cancer, neurological disorders, infectious diseases, cardiovascular, and metabolic diseases. Medical devices include products for cardiovascular, orthopedic, neurovascular care, general surgery, and vision care fields.

Johnson & Johnson has a significant global presence, operating in over 60 countries with more than 275 subsidiaries. The company's operations are divided into four main regions: the United States, Europe, the Western Hemisphere (excluding the U.S.), and Asia-Pacific, Africa. Manufacturing units are located in the U.S., Europe, Asia-Pacific, Africa, the Western Hemisphere (excluding the U.S.), and Latin America. The United States is the largest contributor to Johnson & Johnson's total revenue, accounting for 51.17% in fiscal year 2024.

Johnson & Johnson has consistently maintained a strong brand reputation. For the 22nd consecutive year, the company was named to Fortune's World's Most Admired Companies list in 2024, ranking #2 in the Pharmaceutical Industry and #27 on the overall Top 50 All-Stars list. In 2023, Johnson & Johnson was recognized as the pharmaceutical industry's most valuable company and strongest brand for the fifth year in a row, despite a slight drop in brand value, reflecting a broader industry trend. In 2023, Johnson & Johnson embarked on a new era, uniting its Innovative Medicine and MedTech businesses under the Johnson & Johnson name and revamping its iconic logo, while maintaining its core values.

Johnson & Johnson's stock ownership is a mix of institutional, retail, and individual investors. Institutional investors hold a significant portion, with some reports indicating around 74% ownership as of September 2025, or approximately 40.37% according to other data. Major institutional shareholders include Vanguard Group Inc, BlackRock, Inc., State Street Corp, JPMorgan Chase & Co, Geode Capital Management, Llc, Morgan Stanley, State Farm Mutual Automobile Insurance Co, and Fidelity 500 Index Fund (FXAIX). Key individual shareholders include Alex Gorsky, Joaquin Duato, Paulus Stoffels, Ph.D., Jennifer Taubert, and Joseph J. Wolk.